Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Sanij E, Hannan KM, Xuan J, Yan S, Ahern JE, Trigos AS, Brajanovski N, Son J, Chan KT, Kondrashova O, Lieschke E, Wakefield MJ, Frank D, Ellis S, Cullinane C, Kang J, Poortinga G, Nag P, Deans AJ, Khanna KK, Mileshkin L, McArthur GA, Soong J, Berns EMJJ, Hannan RD, Scott CL, Sheppard KE, Pearson RB. Sanij E, et al. Among authors: sheppard ke. Nat Commun. 2020 May 26;11(1):2641. doi: 10.1038/s41467-020-16393-4. Nat Commun. 2020. PMID: 32457376 Free PMC article.
Second AKT: the rise of SGK in cancer signalling.
Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Bruhn MA, et al. Among authors: sheppard ke. Growth Factors. 2010 Dec;28(6):394-408. doi: 10.3109/08977194.2010.518616. Epub 2010 Oct 5. Growth Factors. 2010. PMID: 20919962 Review.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA. Kinross KM, et al. Among authors: sheppard ke. J Clin Invest. 2012 Feb;122(2):553-7. doi: 10.1172/JCI59309. Epub 2012 Jan 3. J Clin Invest. 2012. PMID: 22214849 Free PMC article.
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Sheppard K, et al. Crit Rev Oncog. 2012;17(1):69-95. doi: 10.1615/critrevoncog.v17.i1.60. Crit Rev Oncog. 2012. PMID: 22471665 Review.
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study. Cowin PA, et al. Among authors: sheppard ke. Cancer Res. 2012 Aug 15;72(16):4060-73. doi: 10.1158/0008-5472.CAN-12-0203. Cancer Res. 2012. PMID: 22896685
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Bruhn MA, et al. Among authors: sheppard ke. Cancer Manag Res. 2013 Aug 26;5:281-92. doi: 10.2147/CMAR.S35178. eCollection 2013. Cancer Manag Res. 2013. PMID: 24009430 Free PMC article. Review.
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB. Sheppard KE, et al. Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3. Eur J Cancer. 2013. PMID: 24011934
75 results